Lexaria Financial Statements From 2010 to 2025

Stocks USA . 
Stock . Lexaria Bioscience Corp
LEXX Stock  USD 1.54  0.01  0.65%   
Lexaria Bioscience financial statements provide useful quarterly and yearly information to potential Lexaria Bioscience Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Lexaria Bioscience financial statements helps investors assess Lexaria Bioscience's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Lexaria Bioscience's valuation are summarized below:
Gross Profit
494.2 K
Market Capitalization
26.9 M
Enterprise Value Revenue
36.2037
Revenue
496.9 K
Earnings Share
(0.52)
We have found one hundred twenty available fundamental ratios for Lexaria Bioscience, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Lexaria Bioscience last-minute market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 120.9 M in 2025. Enterprise Value is likely to rise to about 122.2 M in 2025

Lexaria Bioscience Total Revenue

398,873

Check Lexaria Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexaria Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 129 K, Interest Expense of 107.8 K or Other Operating Expenses of 7.5 M, as well as many indicators such as Price To Sales Ratio of 140, Dividend Yield of 0.0 or PTB Ratio of 57.61. Lexaria financial statements analysis is a perfect complement when working with Lexaria Bioscience Valuation or Volatility modules.
  
Check out the analysis of Lexaria Bioscience Correlation against competitors.

Lexaria Bioscience Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets10.7 M10.2 M4.7 M
Slightly volatile
Other Current Liabilities1.3 M1.2 M287.9 K
Slightly volatile
Total Current Liabilities1 M989.5 K498.2 K
Very volatile
Total Stockholder Equity9.7 M9.2 M4.3 M
Slightly volatile
Property Plant And Equipment Net333.1 K350.6 K681.2 K
Slightly volatile
Accounts Payable1.3 M1.2 M273 K
Slightly volatile
Cash7.8 M7.5 M3 M
Slightly volatile
Non Current Assets Total1.3 M872.8 K949.4 K
Pretty Stable
Cash And Short Term Investments7.9 M7.5 M3.1 M
Slightly volatile
Common Stock Total Equity95.1 K90.6 K61.4 K
Slightly volatile
Common Stock Shares Outstanding15 M14.2 M6.1 M
Slightly volatile
Liabilities And Stockholders Equity10.7 M10.2 M4.7 M
Slightly volatile
Non Current Liabilities Total93.5 K98.4 K60.2 K
Slightly volatile
Other Current Assets1.4 M1.4 M414.3 K
Slightly volatile
Other Stockholder Equity72 M68.6 M30.3 M
Slightly volatile
Total Liabilities577.9 K1.1 M512.2 K
Very volatile
Property Plant And Equipment Gross1.3 M816.5 K870.5 K
Pretty Stable
Total Current Assets9.5 M9.1 M3.8 M
Slightly volatile
Common Stock8.8 K9.3 K33.7 K
Pretty Stable
Short and Long Term Debt Total117.4 K123.6 K397.2 K
Slightly volatile
Net Receivables166.2 K177.6 K168.3 K
Slightly volatile
Short Term Debt24 K25.2 K337.3 K
Slightly volatile
Intangible Assets623.9 K594.2 K253.5 K
Slightly volatile
Net Tangible Assets5.5 M8.6 M4.8 M
Slightly volatile
Net Invested Capital5.9 M9.2 M4.7 M
Slightly volatile
Net Working Capital5 M7.8 M4.1 M
Slightly volatile
Property Plant Equipment372.5 K423.1 K223.4 K
Slightly volatile
Short Term Investments61 K64.2 K103.3 K
Slightly volatile
Capital Stock13.5 K14.2 K52.3 K
Slightly volatile
Long Term Debt24.5 K27.6 K30.1 K
Slightly volatile
Capital Lease Obligations124.6 K158 K123.6 K
Very volatile
Short and Long Term Debt6.3 K7.1 K7.8 K
Slightly volatile

Lexaria Bioscience Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses7.5 M7.2 M4.1 M
Slightly volatile
Total Operating Expenses7.5 M7.1 M3.9 M
Slightly volatile
Total Revenue398.9 K417.9 K451.1 K
Pretty Stable
Cost Of Revenue4.1 K4.3 K188.2 K
Slightly volatile
Selling General Administrative2.5 M4.4 M2.8 M
Slightly volatile
Selling And Marketing Expenses154.5 K234.9 K195.4 K
Slightly volatile
Research Development2.9 M2.7 M1.1 M
Slightly volatile
Reconciled Depreciation94.5 K87.6 K54.9 K
Slightly volatile

Lexaria Bioscience Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures36.8 K38.7 K132.2 K
Pretty Stable
End Period Cash Flow7.8 M7.5 M3 M
Slightly volatile
Begin Period Cash Flow1.8 M1.6 M1.9 M
Slightly volatile
Depreciation85.9 K68.5 K79.3 K
Very volatile
Other Non Cash Items190.9 K200.9 K380.4 K
Pretty Stable
Stock Based Compensation538.4 K566.1 K560.2 K
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio140105182
Slightly volatile
PTB Ratio57.6154.870112.8234
Slightly volatile
Days Sales Outstanding25.0326.3466451
Slightly volatile
Book Value Per Share0.07760.08160.7671
Very volatile
Average Payables90.9 K68.7 K98.8 K
Slightly volatile
Stock Based Compensation To Revenue0.710.7486.9014
Slightly volatile
Capex To Depreciation0.760.799116.0091
Slightly volatile
PB Ratio57.6154.870112.8234
Slightly volatile
EV To Sales133106169
Slightly volatile
Payables Turnover9.068.52.1271
Slightly volatile
Sales General And Administrative To Revenue1.11.160240.4151
Slightly volatile
Research And Ddevelopement To Revenue3.674.585.877
Pretty Stable
Capex To Revenue0.07930.08351.1622
Slightly volatile
Cash Per Share0.00240.00250.5343
Pretty Stable
Days Payables Outstanding40.7942.9415.4 K
Slightly volatile
Intangibles To Total Assets0.05840.05240.0655
Pretty Stable
Net Debt To EBITDA4.334.12040.9651
Slightly volatile
Current Ratio0.09820.103418.5069
Very volatile
Tangible Book Value Per Share0.07760.08160.7199
Very volatile
Receivables Turnover14.5513.85382.7378
Slightly volatile
Graham Number0.350.36574.1662
Slightly volatile
Shareholders Equity Per Share0.07760.08160.8196
Very volatile
Debt To Equity0.420.60850.1418
Pretty Stable
Capex Per Share0.00340.00360.0362
Very volatile
Average Receivables89.8 K166.6 K163.8 K
Slightly volatile
Revenue Per Share0.04060.04270.0554
Slightly volatile
Interest Debt Per Share0.05710.06010.0297
Slightly volatile
Debt To Assets0.20.35740.0778
Slightly volatile
Operating Cycle25.0326.34661.5 K
Slightly volatile
Price Book Value Ratio57.6154.870112.8234
Slightly volatile
Days Of Payables Outstanding40.7942.9415.4 K
Slightly volatile
Company Equity Multiplier1.551.70251.144
Slightly volatile
Long Term Debt To Capitalization0.130.250.1354
Slightly volatile
Total Debt To Capitalization0.210.37830.1045
Very volatile
Debt Equity Ratio0.420.60850.1418
Pretty Stable
Quick Ratio0.09820.103417.2649
Very volatile
Net Income Per E B T1.161.00.9447
Slightly volatile
Cash Ratio0.0440.046313.4843
Pretty Stable
Days Of Sales Outstanding25.0326.3466451
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.780.820.9908
Slightly volatile
Price To Book Ratio57.6154.870112.8234
Slightly volatile
Fixed Asset Turnover0.30.320230.5559
Pretty Stable
Debt Ratio0.20.35740.0778
Slightly volatile
Price Sales Ratio140105182
Slightly volatile
Asset Turnover0.320.30710.0897
Slightly volatile
Price Fair Value57.6154.870112.8234
Slightly volatile

Lexaria Bioscience Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap120.9 M115.2 M26 M
Slightly volatile
Enterprise Value122.2 M116.4 M24.1 M
Slightly volatile

Lexaria Fundamental Market Drivers

Cash And Short Term Investments6.6 M

Lexaria Upcoming Events

12th of April 2024
Upcoming Quarterly Report
View
12th of July 2024
Next Financial Report
View
29th of February 2024
Next Fiscal Quarter End
View
19th of November 2024
Next Fiscal Year End
View
30th of November 2023
Last Quarter Report
View
31st of August 2023
Last Financial Announcement
View

About Lexaria Bioscience Financial Statements

Lexaria Bioscience investors use historical fundamental indicators, such as Lexaria Bioscience's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexaria Bioscience. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue4.5 K4.7 K
Total Revenue417.9 K398.9 K
Cost Of Revenue4.3 K4.1 K
Stock Based Compensation To Revenue 0.75  0.71 
Sales General And Administrative To Revenue 1.16  1.10 
Research And Ddevelopement To Revenue 4.58  3.67 
Capex To Revenue 0.08  0.08 
Revenue Per Share 0.04  0.04 
Ebit Per Revenue 0.27  0.28 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CRMSalesforce
CCitigroup
GMGeneral Motors

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY